A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
Status:
Recruiting
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
This is a phase 1b/2 open-label study to evaluate the safety and efficacy of sacituzumab
govitecan-hziy in combination with chemoimmunotherapy (cyclophosphamide, N-803, and PD-L1
t-haNK) in subjects with Triple Negative Breast Cancer (TNBC) after at least 2 prior
treatments for metastatic disease.